Êtes-vous un étudiant de l'EPFL à la recherche d'un projet de semestre?
Travaillez avec nous sur des projets en science des données et en visualisation, et déployez votre projet sous forme d'application sur GraphSearch.
Concept
Sirtex
Résumé
Sirtex Medical Limited is a medical device company, providing radioactive treatment for inoperable liver cancer called SIR-Spheres microspheres. Sirtex was established in 1997 in Australia and currently maintains offices and manufacturing facilities in the U.S., Australia, Germany and Singapore. Following an acquisition by China Grand Pharmaceutical and CDH Genetech, Sirtex de-listed from the Australian Securities Exchange (ASX:SRX) on Monday, September 24, 2018.
The company is currently headed by Kevin R. Smith, who was appointed as CEO on October 16, 2019.
When SIR-Spheres microspheres are used to treat liver cancer, the treatment is called selective internal radiation therapy (called SIRT). This is a relatively new treatment option for people suffering inoperable liver cancer. SIR-Spheres are very small radioactive beads about one third the size of a human hair width that are injected into tumors within the liver.
The radioactive microspheres have a half-life of about 64 hours. They are administered by a trained interventional radiologist who specializes in minimally invasive, targeted treatments. The procedure is usually performed under local sedation. A small incision is made in the patient's groin and a flexible catheter is guided into the liver through the femoral artery in the leg up to the tumor sites. The catheter is moved through the hepatic artery and positioned by the interventional radiologist to allow for targeted infusion of the SIR-Spheres microspheres to the site of the tumors. The microspheres take approximately 15 minutes to be infused, the whole procedure taking about one hour. Most patients are discharged within 24 hours.
Primary liver cancer, or hepatocellular carcinoma (HCC) is the most common form of liver cancer, responsible for about 90% of the primary malignant liver tumors in adults. Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally. More than 600,000 cases of liver cancer are diagnosed worldwide each year.
Source officielle
À propos de ce résultat
Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.